| Popis: |
As inhibitors of tyrosine kinases have become more widely used in anticancer therapy, detailed understanding of their pharmacokinetic profile is increasingly essential for the improvement of treatment outcomes. Herein, the metabolism in liver microsomes in animal models and humans was studied. Clarification of which liver enzymes, specifically cytochromes P450 (CYP), are involved in the metabolism of vandetanib, cabozantinib and, lenvatinib, may play a key role in oncology practice, as these anticancer drugs are administrated in combination with other drugs. This co-administration may pose a risk of drug interactions, which may result in decreased efficacy or increased drug-related toxicity. To elucidate the metabolism of our selected anticancer drugs in human liver, the same approaches were gradually used- correlation analysis using human liver microsomes from 12 different donors, inhibition studies, and the use of recombinant CYP. In addition, an approach with animal liver microsomes that were premedicated with inducers of individual CYP was used to elucidate vandetanib metabolism in rat liver. Our first studied tyrosine kinase inhibitor was vandetanib. In the first paper, we studied its metabolism in humans through various approaches, and subsequently in another publication in rat. The... |
